EGFR and neoplasm: However, novel combinations of anti-EGFR antibodies linked to inhibitors targeting dysregulated cancer cell–associated pathways might offer advantages with regard to (i) specific delivery of the inhibitor to tumor cells with a likely perturbed cell cycle transition axis and (ii) systemic cytotoxicity reduction.